FR2581060B1
(fr)
*
|
1985-04-25 |
1988-07-01 |
Pf Medicament |
Procede industriel d'obtention du midalcipran
|
FR2581059B1
(fr)
*
|
1985-04-25 |
1988-04-22 |
Pf Medicament |
Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z)
|
WO1995022521A1
(fr)
*
|
1994-02-22 |
1995-08-24 |
Asahi Kasei Kogyo Kabushiki Kaisha |
Derive d'aminoalkylcyclopropane
|
CA2134038C
(en)
*
|
1994-06-16 |
1997-06-03 |
David Taiwai Wong |
Potentiation of drug response
|
EP0714663A3
(de)
|
1994-11-28 |
1997-01-15 |
Lilly Co Eli |
Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
|
DE69607904T2
(de)
*
|
1995-08-16 |
2000-10-05 |
Eli Lilly And Co., Indianapolis |
Potenzierung von Serotonin-Wirkstoffresponz
|
FR2752732B1
(fr)
*
|
1996-08-28 |
1998-11-20 |
Pf Medicament |
Forme galenique a liberation prolongee de milnacipran
|
EP1434763B1
(de)
*
|
2001-10-12 |
2018-01-17 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamyl vasopressin v1a antagonisten
|
US6602911B2
(en)
|
2001-11-05 |
2003-08-05 |
Cypress Bioscience, Inc. |
Methods of treating fibromyalgia
|
US6635675B2
(en)
|
2001-11-05 |
2003-10-21 |
Cypress Bioscience, Inc. |
Method of treating chronic fatigue syndrome
|
US20040034101A1
(en)
*
|
2001-11-05 |
2004-02-19 |
Cypress Bioscience, Inc. |
Treatment and prevention of depression secondary to pain (DSP)
|
EP1499309A4
(de)
*
|
2002-04-24 |
2008-05-28 |
Cypress Bioscience Inc |
Prävention und behandlung von funktionellen somatischen erkrankungen, einschliesslich stressbedingten erkrankungen
|
US7038085B2
(en)
*
|
2002-10-25 |
2006-05-02 |
Collegium Pharmaceutical, Inc. |
Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
|
FR2851163B1
(fr)
|
2003-02-14 |
2007-04-27 |
|
Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
|
ES2310715T3
(es)
|
2003-02-14 |
2009-01-16 |
Pierre Fabre Medicament |
Uso del enantiomero (1s,2r) del milnacipran para la preparacion de un medicamento.
|
JP2006523674A
(ja)
*
|
2003-04-18 |
2006-10-19 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
慢性閉塞性肺疾患(copd)のための組合せ治療法
|
MXPA06001738A
(es)
*
|
2003-08-15 |
2006-05-12 |
Lundbeck & Co As H |
Derivados de ciclopropilo como antagonistas del receptor nk3.
|
CN1867549B
(zh)
*
|
2003-08-15 |
2011-07-06 |
H·隆德贝克有限公司 |
作为nk3受体拮抗剂的环丙基衍生物
|
DK1691811T3
(da)
|
2003-12-11 |
2014-10-20 |
Sunovion Pharmaceuticals Inc |
Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
|
EP1737473A4
(de)
*
|
2004-04-19 |
2009-08-26 |
Noven Therapeutics Llc |
Lithium-kombinationen und relevante verwendungen
|
US9597314B2
(en)
|
2005-03-22 |
2017-03-21 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamylalkanoic acids for treating premenstrual disorders
|
TW200719886A
(en)
*
|
2005-04-22 |
2007-06-01 |
Wyeth Corp |
Dihydrobenzofuran derivatives and uses thereof
|
JP2008538572A
(ja)
*
|
2005-04-22 |
2008-10-30 |
ワイス |
ジヒドロベンゾフラン誘導体およびその使用
|
MX2007013021A
(es)
*
|
2005-04-22 |
2008-01-11 |
Wyeth Corp |
Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
|
CA2611724C
(en)
*
|
2005-06-10 |
2014-07-29 |
Pierre Fabre Medicament S.A. |
Stabilized milnacipran formulation
|
JP2009500043A
(ja)
*
|
2005-07-08 |
2009-01-08 |
ブレインセルス,インコーポレイティド |
神経新生を調節する薬剤及び条件を同定する方法
|
PL1910346T3
(pl)
|
2005-07-19 |
2019-09-30 |
Azevan Pharmaceuticals, Inc. |
Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny
|
US20090203750A1
(en)
*
|
2005-08-24 |
2009-08-13 |
Alan Kozikowski |
5-HT2C Receptor Agonists as Anorectic Agents
|
US7994220B2
(en)
*
|
2005-09-28 |
2011-08-09 |
Cypress Bioscience, Inc. |
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
EP2377530A3
(de)
|
2005-10-21 |
2012-06-20 |
Braincells, Inc. |
Modulation von Neurogenese durch PDE-Hemmung
|
EP2314289A1
(de)
|
2005-10-31 |
2011-04-27 |
Braincells, Inc. |
Gaba-rezeptor-vermittelte modulation von neurogenese
|
JPWO2007086493A1
(ja)
*
|
2006-01-27 |
2009-06-25 |
旭化成ファーマ株式会社 |
経鼻投与用薬剤
|
US20080319083A1
(en)
*
|
2006-01-27 |
2008-12-25 |
Asahi Kasei Pharma Corporation |
Medicine for transnasal administration
|
FR2912057B1
(fr)
*
|
2007-02-07 |
2009-04-17 |
Sanofi Aventis Sa |
Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
CA2644662A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
New therapeutic combinations for the treatment of depression
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
WO2007134077A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
CA2651813A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
TW200817003A
(en)
*
|
2006-07-31 |
2008-04-16 |
Sanofi Aventis |
Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
|
AU2007292848A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
US20100016274A1
(en)
*
|
2006-09-14 |
2010-01-21 |
Koppel Gary A |
Beta-lactam cannabinoid receptor modulators
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
US20080167363A1
(en)
*
|
2006-12-28 |
2008-07-10 |
Braincells, Inc |
Modulation of Neurogenesis By Melatoninergic Agents
|
WO2008086483A2
(en)
*
|
2007-01-11 |
2008-07-17 |
Braincells, Inc. |
Modulation of neurogenesis with use of modafinil
|
US20100145099A1
(en)
*
|
2007-02-28 |
2010-06-10 |
Ranbaxy Laboratories Limited |
Novel polymorphic forms of milnacipran hydrochloride
|
WO2009023820A1
(en)
*
|
2007-08-16 |
2009-02-19 |
Cypress Biosciences, Inc. |
Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination
|
US20090069431A1
(en)
*
|
2007-09-12 |
2009-03-12 |
Protia, Llc |
Deuterium-enriched milnacipran
|
EP2288345B1
(de)
|
2008-04-18 |
2015-06-10 |
University College Dublin National University Of Ireland, Dublin |
Psychopharmazeutika
|
WO2010021681A2
(en)
*
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
WO2010036773A1
(en)
*
|
2008-09-24 |
2010-04-01 |
Concert Pharmaceuticals, Inc. |
Deuterated l-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives
|
FR2941454B1
(fr)
|
2009-01-29 |
2011-04-01 |
Pf Medicament |
Proced de synthese du (1s,2r)-milnacipran
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
US20100274050A1
(en)
*
|
2009-04-23 |
2010-10-28 |
Glenmark Generics Limited |
Solid milnacipran and process for the preparation of the same
|
WO2010129689A1
(en)
*
|
2009-05-05 |
2010-11-11 |
Forest Laboratories Holdings Limited |
Milnacipran formulations
|
WO2011016057A2
(en)
|
2009-08-05 |
2011-02-10 |
Lupin Limited |
Controlled release pharmaceutical compositions of milnacipran
|
US8865937B2
(en)
*
|
2009-11-06 |
2014-10-21 |
Mahendra G. Dedhiya |
Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
|
WO2011092065A1
(en)
|
2010-01-29 |
2011-08-04 |
Nicox S.A. |
Nitric oxide releasing compounds for the treatment of neurophatic pain
|
PL2587919T3
(pl)
|
2010-07-01 |
2018-05-30 |
Azevan Pharmaceuticals, Inc. |
Sposoby leczenia zespołu stresu pourazowego
|
WO2012028922A2
(en)
|
2010-08-30 |
2012-03-08 |
Lupin Limited |
Controlled release pharmaceutical compositions of milnacipran
|
WO2012059933A1
(en)
|
2010-11-03 |
2012-05-10 |
Arch Pharmalabs Limited |
A new process for preparing optically pure milnacipran and its pharmaceutically acceptable salts.
|
WO2012145234A2
(en)
*
|
2011-04-21 |
2012-10-26 |
Emory University |
Cyclopropyl derivatives and methods of use
|
WO2014009767A1
(en)
|
2012-07-07 |
2014-01-16 |
Micro Labs Limited |
An improved process for the preparation of 1-aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers and salts
|
WO2014203277A2
(en)
*
|
2013-06-19 |
2014-12-24 |
Msn Laboratories Private Limited |
Process for the preparation of (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanearboxamide hydrochloride
|
IN2013MU03122A
(de)
|
2013-09-30 |
2015-07-17 |
Cadila Healthcare Ltd |
|
PL3122743T3
(pl)
|
2014-03-28 |
2023-05-02 |
Azevan Pharmaceuticals, Inc. |
Kompozycje i sposoby leczenia chorób neurodegeneracyjnych
|
MX2020002762A
(es)
|
2017-09-15 |
2020-09-17 |
Azevan Pharmaceuticals Inc |
Composiciones y métodos para tratar una lesión cerebral.
|
US20240024288A1
(en)
|
2019-07-19 |
2024-01-25 |
Bioxcel Therapeutics, Inc. |
Non-sedating dexmedetomidine treatment regimens
|
US11806334B1
(en)
|
2023-01-12 |
2023-11-07 |
Bioxcel Therapeutics, Inc. |
Non-sedating dexmedetomidine treatment regimens
|